{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.17","upperLimit":"23.95","value":"9.72"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"}],"units":"Participants"}],"description":"Durability of complete response (CR) was defined as the time from first observed CR to the documented treatment failure. Patients without treatment failure were censored at the last disease assessment not showing treatment failure, where treatment failure was defined as high-grade disease recurrence, disease progression, or death, whichever occurred earlier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with Carcinoma in situ (CIS) with or without concomitant high-grade Ta or T1 papillary disease","id":"OG000","title":"Carcinoma in Situ"}],"paramType":"MEDIAN","populationDescription":"Patients who achieved CR","reportingStatus":"POSTED","timeFrame":"Up to 57 months","title":"Durability of Complete Response in Patients With CIS (With or Without Concomitant Ta or T1 Papillary Disease) Who Achieve a Complete Response.","type":"SECONDARY","unitOfMeasure":"Months"}